Shares of Aurobindo Pharma Limited slipped on Monday, 15 June, touching an intraday low of Rs 1,446 on the NSE after the US Food and Drug Administration classified a manufacturing facility of its subsidiary under the ‘Official Action Indicated’ category.

Eugia Pharma Specialities, a wholly owned subsidiary of Aurobindo Pharma, operates the flagged unit. Unit III is a formulation manufacturing plant located in Pashamylaram, Sangareddy district, Telangana.

FDA inspectors visited the plant between 27 January and 6 February 2026. By the end of that visit, they raised 11 observations against the facility. 

The company disclosed on 12 June that the USFDA had classified the inspection as OAI. OAI means the regulator found objectionable conditions that may warrant regulatory or administrative action. 

The classification may affect approvals of new products from the facility until the regulatory concerns are addressed to the FDA’s satisfaction.

Aurobindo Pharma told stock exchanges that the development will not affect its financial performance or day-to-day operations. The company also reaffirmed its focus on quality standards across its plants.

At 10:56 am, shares were trading at Rs 1,447.60 on the NSE, down 1.71% from the previous close of Rs 1,472.80. 

Unlock profitable opportunities every day! Tradz by EquityPandit provides actionable intraday trading signals for stocks and futures. Don’t miss out – download Tradz by EquityPandit and start winning now!